| Title |
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, January 2013
|
| DOI | 10.2147/tcrm.s30349 |
| Pubmed ID | |
| Authors |
Elisavet Paplomata, Ruth O’Regan |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 2 | 9% |
| Researcher | 2 | 9% |
| Student > Ph. D. Student | 1 | 5% |
| Student > Bachelor | 1 | 5% |
| Unknown | 16 | 73% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 2 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Agricultural and Biological Sciences | 1 | 5% |
| Medicine and Dentistry | 1 | 5% |
| Chemistry | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 16 | 73% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2022.
All research outputs
#5,303,441
of 25,608,265 outputs
Outputs from Therapeutics and Clinical Risk Management
#262
of 1,322 outputs
Outputs of similar age
#51,590
of 290,137 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#3
of 8 outputs
Altmetric has tracked 25,608,265 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,322 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,137 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.